Characterization of pyruvate dehydrogenase complex E1

alpha and beta subunits of *Mycoplasma synoviae*

Shijun Bao^{1*}, Xiaoqin Ding¹, Shengqing Yu², Chan Ding^{2*}

¹College of Veterinary Medicine, Gansu Agricultural University, 1 Yingmencun, Lanzhou 730070, P.R. China.

²Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 518 Ziyue Road, Minhang District, Shanghai 200241, P.R. China.

*Corresponding author:

Tel: +86-931-7631220; Fax: +86-931-7631220;

E-mail: bsjdy@126.com (S J Bao)

Tel: +86-21-34293441; fax: +86 21 34293441;

E-mail: shoveldeen@shvri.ac.cn (C. Ding).

ABSTRACT *Mycoplasma synoviae* (MS) is an important pathogen, causing enormous economic losses to the poultry industry worldwide every year. Therefore, the studies on MS will lay the foundation for diagnosis, prevention and treatment of MS infection. In this study, primers designed based on the sequences of pyruvate dehydrogenase complex (PDC) E1 alpha and beta subunit genes (*pdhA* and *pdhB*, respectively) of MS WVU1853 strain in GenBank were used to amplify the *pdhA* and *pdhB* genes of MS WVU1853 strain through PCR. Then the prokaryotic expression vectors pET-pdhA and pET-pdhB were constructed and were expressed in *Escherichia coli* BL21(DE3) cells. Subsequently, the recombinant proteins rMSPDHA and rMSPDHB were purified and anti-rMSPDHA and anti-rMSPDHB sera were prepared by immunizing rabbits, respectively. Finally, the subcellular localization of PDHA and PDHB in MS, binding activity of rMSPDHA and rMSPDHB to chicken plasminogen (Plg) and human fibronectin (Fn), complement-dependent mycoplasmacidal assays, and adherence and adherence inhibition assays were accomplished. The results showed that PDHA and PDHB

were distributed both on the surface membrane and within soluble cytosolic fractions of MS cells. The rMSPDHA and rMSPDHB presented binding activity with chicken Plg and human Fn. The rabbit anti-rMSPDHA and anti-rMSPDHB sera had distinct mycoplasmacidal efficacy in the presence of guinea pig complement, and the adherence of MS to DF-1 cells pretreated with Plg was effectively inhibited by treatment with anti-rMSPDHA or anti-rMSPDHB sera. Hence, the study indicates that the surface-associated MSPDHA and MSPDHB are the adhesion-related factors of MS that contributes to bind to Plg/Fn and adhesion to DF-1 cells.

KEYWORDS *Mycoplasma synoviae*; pyruvate decarboxylase; cloning; biological characteristics

Mycoplasma synoviae (MS) is an important pathogen exerting significant economic impact on poultry industry worldwide. MS infections can lead to a range of diseases, from subclinical to severe ailments. In chickens, local infection of MS frequently causes subclinical disease of the upper respiratory tract (Buim et al., 2009; Khiari et al., 2010; Landman, 2014; Wetzel et al., 2010), while systemic infection of MS causes synovitis (Wetzel et al., 2010). Furthermore, coinfection of MS with other respiratory pathogens, such as Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus, *Escherichia coli*, and *Mycoplasma meleagridis*, can induce airsacculitis, thereby further increasing economic losses (Giambrone et al., 1977; Kleven, 1998; Limpavithayakul et al., 2016; May et al., 2007; Rhoades, 1977; Springer et al., 1974; Vardaman et al., 1975). In addition to respiratory tract tropism strains and arthropathic strains, oviduct tropism strains can induce eggshell apex abnormalities without any physical abnormalities (Limpavithayakul et al., 2016). Therefore, research on MS can establish the theoretical foundation for further development of vaccines, diagnostic reagents, and therapeutic drugs against MS infections.

The pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA (Patel and Roche, 1990; Perham, 1991; Reed, 2001). Therefore, the

PDC occupies a key position in the oxidation of glucose by linking the glycolytic pathway to the oxidative pathway of the tricarboxylic acid cycle. In prokaryotes and eukaryotes, the PDC consists of three catalytic enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). The PDC E1 (EC 1.2.4.1) is a thiamin diphosphate-dependent enzyme and catalyzes the oxidative decarboxylation of pyruvate, which is the rate-limiting step in the overall activity of the PDC (Linn et al., 1969a; Linn et al., 1969b; Patel et al., 2014). Previous studies have shown that the PDC E1 is a heterotetramers ($\alpha_2\beta_2$) consisting of two alpha subunits and two beta subunits (Dahl et al., 1987; Patel et al., 2014; Payton et al., 1977). In some *Mycoplasma* spp., the E1 beta subunit of PDC acts as an immunogenic protein or plasminogen (Plg)/fibronectin (Fn) binding proteins (Dallo et al., 2002; Sun et al., 2014; Thomas et al., 2013); however, there are still no reports on PDC E1 of MS. Therefore, in the present study, the genes encoding the alpha and beta subunits of PDC of MS were amplified and expressed in *E. coli*, respectively, and their biological characteristics were investigated.

MATERIALS AND METHODS

Enzymes and main reagents. Restriction enzymes, T4 DNA ligase and PrimeSTAR® HS DNA polymerase, were purchased from TaKaRa (Dalian, China). Complement sera (guinea pig source) were bought from the Control Institute of Veterinary Bioproducts and Pharmaceuticals (Beijing, China). The reagents used for cell culture were obtained from Gibco (Grand Island, NY, USA). Other chemicals used in this study were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA) or Sangon Biotech (Shanghai, China).

Bacterial strains, cell line, culture conditions, and plasmids. *M. synoviae* WVU1853 strain was obtained from the Chinese Veterinary Culture Collection Center (CVCC, Beijing, China) and cultured in Frey's medium (Frey et al., 1968) at 37°C in an atmosphere of 5% CO₂. *E. coli* strains DH5 α and BL21(DE3) (TransGen, Beijing, China), which were used as

prokaryotic host for cloning and expression, respectively, were cultured in Luria-Bertani (LB) broth or plated on LB agar supplemented with 50 µg/mL kanamycin at 37°C. DF-1 cells, a continuous cell line of chicken embryo fibroblasts, were obtained from the American Type Culture Collection (Manassas, VA, USA) and certified to be free of Mycoplasma contamination, and were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin at 37°C in an atmosphere of 5% CO₂. The pET-28a(+) expression vector was obtained from Novagen (Madison, WI, USA), and pET-InaZNEGFP was constructed in our previous study (Bao et al., 2015).

Cloning and expression of *pdhA* and *pdhB* genes of MS, and protein purification. The complete genome sequence of MS strain WVU1853 available in GenBank (www.ncbi.nlm.nih.gov/genbank/) revealed that the open reading frame (ORF) of MS *pdhA* gene containing eight TGA codons encodes tryptophan in *Mycoplasma* spp., but acts as stop codons in *E. coli*. Therefore, primers *pdhA*-F1/*pdhA*-R1, *pdhA*-F2/*pdhA*-R2, *pdhA*-F3/*pdhA*-R3, *pdhA*-F4/*pdhA*-R4, *pdhA*-F5/*pdhA*-R5, *pdhA*-F6/*pdhA*-R6, *pdhA*-F7/*pdhA*-R7, *pdhA*-F8/*pdhA*-R8, and *pdhA*-F9/*pdhA*-R9 (Table 1) were designed for site-directed mutagenesis and used in overlapping PCRs to amplify *pdhA*, while primers *pdhB*-F/*pdhB*-R (Table 1) were employed to amplify *pdhB*. The full-length mutated *pdhA* and *pdhB* genes were amplified with the introduction of *Bam*HI and *Xho*I restriction enzyme sites, respectively, and the recombinant plasmids pET-*pdhA* and pET-*pdhB* were constructed and transformed into *E. coli* BL21(DE3) cells, respectively. Recombinant rMSPDHA and rMSPDHB were then expressed through 1.0 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) induction and purified using Ni-NTA His-Bind® Resin Kit (Novagen, San Diego, USA). The purified protein products were quantified by using BCA Protein Assay Kit (Thermo Scientific-Pierce, Rockford, IL, USA) and analyzed by 10% SDS-PAGE with Coomassie blue staining.

Preparation of anti-sera against rMSPDHA, rMSPDHB. The anti-sera against rMSPDHA, rMSPDHB, and MS whole cells were prepared by injecting female New Zealand White rabbits with rMSPDHA, rMSPDHB, and inactivated whole-cell MS, respectively. Three female rabbits were individually immunized four times by subcutaneous injection into the back with purified recombinant proteins (800 µg) or inactivated whole-cell MS (10^{10} CFU), mixed with Imject[®] Alum adjuvant (Thermo Scientific-Pierce, Waltham, MA, USA), at 2-week intervals. Seven days after the fourth immunization, the rabbits were bled and the antibody titers were measured by indirect ELISA (Bao et al., 2014). Aliquots of the serum samples were placed in 1.5-mL Eppendorf tubes and stored at -40°C for future use. All animal experiments were approved by the Experimental Animal Ethic and Welfare Committee of Gansu Agricultural University (China).

Preparation of MS protein fractions. Membrane and cytosolic proteins fractions from MS were extracted using ReadyPrep[™] Protein Extraction Kit (Membrane I) (Bio-Rad, CA, USA) according to the manufacturer's instructions. Subsequently, the membrane and cytosolic proteins were dissolved in the same volume of protein solubilization buffer and equal volumes of the solutions were respectively subjected to ELISA or Western blot. The MS whole cell protein was prepared by using bacterial lysis buffer (Sangon, Shanghai, China) according to the manufacturer's instructions. Protein quantitation was performed using BCA Protein Assay Kit (Beyotime Institute of Biotechnology, Nan Tong, China).

Analysis of PDHA and PDHB distribution in MS whole cells. To confirm the distribution of PDHA and PDHB in MS whole cells, equal volumes of membrane and cytosolic proteins were subjected to western blot or ELISA. Western blot was performed as described previously (Bao et al., 2014). In brief, the gels were transferred onto nitrocellulose (NC) membranes (Whatman GmbH, Staufien, Germany) and blocked with 5% skim milk for 3 h at room temperature. Following three washes with PBST (3.2 mM Na_2HPO_4 , 0.5 mM KH_2PO_4 , 1.3 mM

KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4), the NC membranes were incubated with rabbit anti-rMSPDHA or anti-rMSPDHB sera (dilution, 1:1000) at 4°C overnight. After washing thrice, the NC membranes were incubated with goat anti-rabbit IgG conjugated to horseradish peroxidase (HRP; Sigma-Aldrich; dilution, 1:8000) and the color reaction was examined using ECL Kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Purified rMSPDHA and rMSPDHB (1.5 µg) were used as positive control and bovine serum albumin (BSA, 1.5 µg) was employed as negative control. The experiment was performed in triplicate and repeated three times.

For ELISA, the 96-well plates were coated with equal volumes of membrane and cytosolic proteins and incubated at 4°C overnight. After washing thrice with PBST, the wells were blocked with 5% skim milk in PBST at 37°C for 3 h. The plates were then washed thrice and rabbit anti-rMSPDHA sera or rabbit anti-rMSPDHB sera (100 µL/well; dilution, 1:1000) were added to the wells and incubated for 2 h at 37°C. After washing, goat anti-rabbit IgG-HRP was added to the wells (100 µL/well; Sigma-Aldrich; dilution, 1:5000) and the plates were incubated at 37°C for 1 h. Finally, the color reaction was conducted by adding soluble tetramethylbenzidine (TMB) substrate solution to the wells (100 µL/well; TIANGEN, Beijing, China) and incubating the plates for 10 min at room temperature. The reaction was stopped with 2 M H₂SO₄ addition. The absorbance was measured at A₄₅₀ using a microplate reader (Bio-Tek Instruments, Winooski, USA). Purified rMSPDHA and rMSPDHB (10 µg/well) were used as positive control and BSA (10 µg/well) was employed as negative control. The experiment was performed in triplicate and repeated three times.

Complement-dependent mycoplasmacidal assays. Complement-dependent mycoplasmacidal activity of rabbit anti-rMSPDHA or anti-rMSPDHB sera was determined as described previously (Bao et al., 2014). MS, grown to mid-logarithmic phase, was washed three times with PBS by centrifugation at 5,000×g for 10 min at 4°C, and re-suspended in PBS at the

final concentration of 6×10^3 CFU/mL. The reaction system was established as follows: 160 μ L of MS suspension and 60 μ L of rabbit anti-rMSPDHA or anti-rMSPDHB sera (1:5) were gently mixed in 1.5-mL Eppendorf tube and incubated at 37°C for 30 min. Then, 30 μ L of diluted complement (1:10) were added, mixed and incubated at 37°C for 1 h. The reaction mixture (50 μ L) was spread onto solid media in a 60-mm dish and incubated at 37°C in 5% CO₂ for 7 days to count the colonies. Rabbit anti-MS sera and pre-immune rabbit sera were employed as positive and negative control, respectively. In addition, controls for complement and PBS were included. All sera (except for complement) used in the experiments were inactivated at 56°C for 30 min. Three independent experiments were performed in triplicate. The mycoplasmacidal coefficient was calculated as follows: [(CFU of pre-immune serum treatment – CFU of antiserum treatment)/(CFU of pre-immune serum treatment)] $\times$ 100.

Binding activity of rMSPDHA and rMSPDHB to Plg and Fn. Western blot and ELISA were used to determine the binding activity of rMSPDHA and rMSPDHB to chicken Plg (Cell Sciences, MA, USA) and human Fn (Sigma-Aldrich) as described previously (Bao et al., 2014). In brief, MS rMSPDHA or rMSPDHB was transferred onto nitrocellulose membranes, incubated with chicken Plg or human Fn, and blots were developed with ECL Kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions.

ELISA was performed to verify the ability of the proteins to bind to Plg and Fn. In brief, the wells of the ELISA plate were coated with chicken Plg or human Fn at a concentration of 50 ng/well and incubated at 4°C overnight. After washing, a range of concentrations of rMSPDHA or rMSPDHB (0, 1, 5, 10, 15, 20, 25, or 30 μ g/mL in PBST) were added to the wells and incubated for 2 h at 37°C. Then, the plates were incubated with rabbit anti-rMSPDHA or anti-rMSPDHB sera (100 μ L/well; dilution, 1:1000) at 37°C for 1.5 h. After washing, goat anti-rabbit IgG-HRP was added to the wells (100 μ L/well; Sigma-Aldrich; dilution, 1:5000), and the plates were incubated at 37°C for 1 h. Subsequently, the color reaction was performed and the

absorbance was measured at A_{450} using a microplate reader (Bio-Tek Instruments). BSA were used as negative control and all experiments were performed in triplicate and repeated thrice.

Adherence and adherence inhibition test. Adherence and adherence inhibition assays were performed as previously described (Bao et al., 2015). *E. coli* surface display vectors pET-InaZN-EGFP-pdhA/pET-InaZN-EGFP-pdhB were constructed, and *E. coli* BL21 (DE3) cells harbouring InaZN-EGFP-pdhA or InaZN-EGFP-pdhB fusion protein were induced by IPTG, centrifuged at 2500 g for 10 min and washed three times with DMEM. Then the DF-1 cells grown to monolayers in 35-mm dishes were washed with DMEM and the pdhA-positive or pdhB-positive *E. coli* cells were added to DF-1 cells at 100 multiplicity of infection (MOI) for 2 h at 37°C in 5% CO₂. After washing with PBS to remove non-adherent *E. coli* cells, 1 ml of 4% paraformaldehyde was added to the monolayers, and the plate was then incubated at room temperature for 10 min. After washing five times with PBS, the cell membranes were labelled with 500 μ l of 10 μ mol l⁻¹ 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Beyotime Institute of Biotechnology, Jiangsu, China) at room temperature for 10 min. After washing five additional times with PBS, the cell nuclei were labelled with 500 μ l of 0.1 μ g ml⁻¹ of 4', 6-diamidino-2-phenylindole (Beyotime Institute of Biotechnology) at room temperature for 10 min and then washed three times with PBS. Finally, the cells were mounted on slides and observed by fluorescent microscopy to evaluate the adhesion properties of the cells. The induced *E. coli* BL21(DE3) cells harboring InaZN-EGFP fusions acted as blank control, and all the experiments were performed in triplicate and repeated thrice.

To further validate the adherence function of MSPDHA and MSPDHB, adherence/adherence inhibition assay was conducted based on a bacteriological assay as previously described (Chen et al., 2011; Song et al., 2012) with slight modifications. For the adherence assay, DF-1 cells grown to a monolayer in a 35-mm dish were washed thrice with PBS and incubated with Plg (10 μ g/mL) for 2 h at 37°C. The cells were then washed with

DMEM and the MS WVU1853 strain was added at a multiplicity of infection of 200 and incubated for 2 h at 37°C and 5% CO₂. Non-adherent MS cells were removed by washing and the infected cells were lysed with 0.25% trypsin (Gibco) and serial dilutions of the cell lysate were then respectively plated onto solid medium and incubated for 96 h at 37°C and 5% CO₂. The MS colonies were counted to determine the adherence frequency. For adherence inhibition assay, the MS WVU1853 strain was incubated with rabbit anti-rMSPDHA/anti-rMSPDHB sera or rabbit anti MS positive sera for 1 h at 37°C and then used to infect the DF-1 cells as described earlier. The pre-immune rabbit sera acted as negative control and all experiments were performed in triplicate and repeated thrice. The percent inhibition was calculated using the following formula: (CFU of negative control – CFU of anti-serum treatment)/(CFU of negative control)] × 100.

Statistical analysis. All data are expressed as the mean ± standard deviation of n independent measurements. The statistical significance of the intergroup differences was evaluated using Student's t-test. The SPSS software (SPSS, Chicago, IL, USA) was used to calculate and analyze and the level of significance was set at P < 0.05 or P < 0.01.

RESULTS

Expression of MS *pdhA* and *pdhB* genes, and purification of recombinant proteins. The full-length mutated *pdhA* and *pdhB* genes were amplified with the designed primers using overlapping PCR, and the recombinant plasmid pET-*pdhA* and pET-*pdhB* were constructed. Sequence analysis indicated that the *pdhA* and *pdhB* genes were 1125 and 993 bp in length, respectively. The tryptophan codons (TGA) in the *pdhA* gene were successfully mutated to TGG. Theoretically, *pdhA* gene encodes a 374-amino-acid protein with a relative molecular weight of approximately 40.642 kDa, while *pdhB* gene encodes a 330-amino-acid protein with a relative molecular weight of approximately 35.854 kDa.

The recombinant plasmids of pET-pdhA and pET-pdhB vectors were respectively transformed into *E. coli* BL21(DE3) cells. The obtained recombinant proteins rMSPDHA and rMSPDHB were expressed by 1.0 mM IPTG induction. The SDS-PAGE results showed that the proportions of recombinant fusion proteins, rMSPDHA and rMSPDHB, were higher in the supernatant than those in the sediment, and their apparent molecular weights were approximately 44 and 39 kDa, respectively (Fig. 1). The purified recombinant proteins presented a single band, respectively (Fig. 2).

Preparation of rabbit anti-sera against rMSPDHA, rMSPDHB, and MS whole cells.

One week after fourth immunization, the rabbits were bled and the reactivity and specificity of the rabbit antisera were respectively tested by ELISA and western blot. The results showed that the ELISA antibody titers of the anti-rMSPDHA, anti-rMSPDHB, or anti MS whole cells sera were higher than 1:20,000. Western blot results demonstrated that both anti-rMSPDHA and anti-rMSPDHB sera can specifically combine with MS bacterial protein and purified rMSPDHA or rMSPDHB (Fig. 3).

Localization of MSPDHA and MSPDHB.

MS PDHA and MS PDHB were detected in the cell membrane fraction proteins (Fig. 4; Lanes 2, 6) and the cell soluble cytosolic fraction proteins of MS (Fig. 4; Lanes 3, 7). Purified rMSPDHA, rMSPDHB (Fig. 4; Lanes 1, 5), and BSA (Fig. 4; Lanes 4, 8) were employed as positive and negative controls, respectively. The anti-rMSPDHA and anti-rMSPDHB sera could specifically combine with the protein of approximately 41kDa and 36 kDa, respectively, while the band size of the binding recombinant protein was about 44 kDa and 39 kDa, respectively. However, both anti-rMSPDHA and anti-rMSPDHB sera had no binding band with BSA, suggesting that MS PDHA and PDHB were present in both the membrane and soluble cytosolic protein fractions of MS cells. And the results also indicated that the content of MS PDHA and PDHB in the membrane fractions was higher than that in the cytosolic fractions. ELISA results (Fig. 5) also revealed that the content

of MS PDHA and PDHB in the membrane fractions was higher than that in the cytosolic fractions ($P < 0.01$).

Complement-dependent mycoplasmacidal assays. As shown in Table 2, Complement-dependent mycoplasmacidal assays revealed obvious difference in mycoplasmacidal activity between anti-rMSPDHA/anti-rMSPDHB sera and pre-immune rabbit serum ($P < 0.01$). In addition, the mycoplasmacidal activity of the rabbit anti-rMSPDHA was more effective than that the anti-rMSPDHB sera, and the mycoplasmacidal rates were 65.6% and 29.89%, respectively.

Binding activity of rMSPDHA and rMSPDHB to Plg and Fn. The ability of rMSPDHA and rMSPDHB to bind to Plg and Fn was examined by western blot and ELISA. The western blot analyses showed that both chicken Plg and human Fn bind to rMSPDHA and rMSPDHB, as indicated by unique bands at 44 and 39 kDa, respectively (Fig. 6). ELISA revealed that both rMSPDHA and rMSPDHB could bind to immobilized chicken Plg or human Fn in a dose-dependent manner (Fig. 7). However, BSA, which was employed as the negative control, showed no obvious binding effect with either chicken Plg or human Fn (Fig. 7).

Adherence and adherence inhibition assays. Adherence and adherence inhibition tests of *E. coli* cells harboring InaZNEGFP-PDHA or InaZNEGFP-PDHB to DF-1 cells showed that the PDHA-and PDHB-positive *E. coli* transformants were able to specifically attach to DF-1 cells, which can be inhibited by rabbit anti-rMSPDHA/anti-rMSPDHB sera (Fig. 8). However, the induced *E. coli* transformants harboring pET-InaZNEGFP were unable to attach to DF-1 cells (Fig. 8), indicating that both MS PDHA and MS PDHB are adhesion-related factors.

To further validate the effect of MSPDHA and MSPDHB on the adherence of MS to DF-1 cells, the adherence and adherence inhibition values were calculated. As table 3 shows that the rabbit anti-rMSPDHA/anti-rMSPDHB sera had significant inhibitory effect on the adherence of

MS to DF-1 cells ($P < 0.01$). There was apparent difference in adherence inhibition rate between the anti-rMSPDHA/anti-rMSPDHB sera and pre-immune rabbit serum ($P < 0.01$), and the anti-rMSPDHA sera were more effective than the anti-rMSPDHB sera at inhibiting adherence ($P < 0.01$). Thus, these results demonstrated that MSPDHA and MSPDHB are adhesion-related proteins.

DISCUSSION

MS is a major pathogen of avian, which is widely distributed around the world and leads to serious economic losses in the world every year. Therefore, the MS association studies will lay the foundation for diagnosis, prevention and treatment of MS infection. Prior to this study, some major immunogenic proteins of MS isolates were identified, including PDC E1 alpha and beta subunit, elongation factor Tu (EF-Tu), enolase, etc. (Bao et al., 2017; Bercic et al., 2008). As a component of the PDC, the PDC E1 not only plays the important role in energy metabolism, but performs additional biological functions, including immunogenicity, adhesion and invasion of pathogenic microorganisms to host cells (Sun et al., 2014; Vastano et al., 2014). Currently, PDC E1 from various plants and yeasts have been separated and identified, but there have been only a few reports on PDC E1 from bacteria. Bacteria-derived PDC E1 catalyzes ethanol production through Entner-Doudoroff pathway, rather than pyruvate generation through glycolysis. Therefore, studies on PDC E1, especially those on PDC E1 from thermophilic bacteria (Van Zyl et al., 2014), have been mainly focused on its biocatalysis, because it is safe, pollution-free, and highly efficient (Taylor et al., 2009). Nevertheless, no study on the PDC E1 of MS has been reported up to present.

In this study, the *pdhA* and *pdhB* of MS were amplified, optimized and expressed in a prokaryotic system, respectively. And both recombinant proteins could express in BL21(DE3) in soluble form. Then anti-rMSPDHA/anti-rMSPDHB sera were prepared. These laid the foundation for study on other biological functions of MS PDHA and PDHB. Subsequently, the

immunogenic proteins with good immunogenicity of MSPDHA and MSPDHB were confirmed by indirect ELISA and western blot, consistent with previous research(Bao et al., 2017). The similar finding has been made in *M. bovis* (Sun et al., 2014).

That the MSPDHA and MSPDHB are present in both the soluble cytosolic fraction and the membrane fraction of MS has been demonstrated, and with higher distribution in the cell membrane fraction than in the cytosolic fraction (Fig.4 and 5). This analysis demonstrates that MSPDHA and MSPDHB are respectively the membrane-associated protein in MS, suggesting that MSPDHA and MSPDHB might possess various biological functions besides the catalytic activity catalyst, such as some membrane-associated proteins have been found in previous studies (Bao et al., 2014; Gao et al., 2018; Salzillo et al., 2017). We suggest that the distribution in the cell membrane fraction of MSPDHA and MSPDHB is consistent with the etiology of adherence to host cells.

We have also demonstrated that rabbit anti-rMSPDHA/anti-rMSPDHB sera displayed a significant complement-dependent mycoplasmacidal effect, and the mycoplasmacidal activity of the rabbit anti-rMSPDHA was more effective than that the anti-rMSPDHB sera (Table 2), the similar biological function of other proteins of MS has been previously reported(Bao et al., 2014; Gao et al., 2018). This suggested that MSPDHA and MSPDHB should play an important role in host immunity against MS infection.

The binding activity of MSPDHA and MSPDHB to chicken Plg and human Fn has been confirmed in the present study. The western blot analyses demonstrate the binding specificity of MSPDHA and MSPDHB to chicken Plg and human Fn (Fig. 6), and the ELISA revealed that the binding of MSPDHA and MSPDHB to chicken Plg or human Fn in a dose-dependent manner. The PDHB acts as fibronectin and plasminogen-binding protein has already been demonstrated in other microorganisms (Dallo et al., 2002; Salzillo et al., 2017; Thomas et al., 2013), but the binding activity of MSPDHA to chicken Plg and human Fn was first confirmation in this study. Those suggested that MSPDHA and MSPDHB are the major Plg/Fn-

binding protein in MS; this could be of great importance for Mycoplasma establishment in the host. Therefore, we speculate that a-enolase is involved in MS adhesion to DF-1 cells.

To confirm the adhesion activity of MSPDHA and MSPDHB to host cells, both E. coli cells harboring InaZNEGFP-pdhA/InaZNEGFP-pdhB and MS were subjected to the adherence and inhibition assay in vitro. In this work the adhesion ability of MSPDHA and MSPDHB to DF-1 cells has been demonstrated, and this adhesion was effectively inhibited by the addition of anti-rMSPDHA/anti-rMSPDHB sera, suggesting that MSPDHA and MSPDHB are adhesion-related proteins on MS cell membrane surface. Based on this, we speculate that MSPDHA and MSPDHB may participate in adhesion, colonization, and invasion of MS to host cells, and may be involved in various clinical and pathologic sequelae of MS infection, such as synovitis, tenosynovitis and arthritis.

CONCLUSIONS

The studies show that the MSPDHA and MSPDHB are surface-exposed proteins with excellent immunogenicity, and that rabbit anti-rMSPDHA/anti-rMSPDHB sera had a significant complement-dependent mycoplasmacidal effect. Furthermore, the findings also demonstrated the binding ability of MSPDHA and MSPDHB to chicken Plg and human Fn, as well as the adherence to DF-1 cells. These results suggested that MSPDHA and MSPDHB play important role in MS metabolism, infection, and immunity, providing the basis for further research on the functions of MSPDHA and MSPDHB.

FUNDING INFORMATION

This work was supported by the National Natural Science Foundation of China (31360620) and Natural Science Foundation of Gansu Province, China (1308RJZA235).

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ACKNOWLEDGMENTS

We are thankful to the Laboratory of Veterinary Lemology, Gansu Agricultural University, China, and the Key Open Laboratory of Shanghai Veterinary Research Institute, CAAS, for providing key laboratory equipment.

REFERENCES

- Bao, S., Guo, X., Yu, S., Ding, J., Tan, L., Zhang, F., Sun, Y., Qiu, X., Chen, G., Ding, C., 2014. Mycoplasma synoviae enolase is a plasminogen/fibronectin binding protein. BMC Vet Res 10, 223.
- Bao, S., J., Ding, X.Q., Xing, X.Y., Fu, X.P., Xue, H.W., Wen, F.Q., 2017. Preliminarily analysis of immune-related membrane proteins from mycoplasma synoviae WVU1853 strain. Acta Veterinary et Zootechnica Sinic 48, 316-323.
- Bao, S., Yu, S., Guo, X., Zhang, F., Sun, Y., Tan, L., Duan, Y., Lu, F., Qiu, X., Ding, C., 2015. Construction of a cell-surface display system based on the N-terminal domain of ice nucleation protein and its application in identification of mycoplasma adhesion proteins. Journal of applied microbiology 119, 236-244.
- Bercic, R.L., Slavec, B., Lavric, M., Narat, M., Bidovec, A., Dovc, P., Bencina, D., 2008. Identification of major immunogenic proteins of Mycoplasma synoviae isolates. Vet Microbiol 127, 147-154.
- Buim, M.R., Mettifofo, E., Timenetsky, J., Kleven, S., Ferreira, A.J.P., 2009. Epidemiological survey on Mycoplasma gallisepticum and M.synoviae by multiplex PCR in commercial poultry. Pesq. Vet. Bras 29, 552-556.
- Chen, H., Yu, S., Shen, X., Chen, D., Qiu, X., Song, C., Ding, C., 2011. The Mycoplasma gallisepticum alpha-enolase is cell surface-exposed and mediates adherence by binding to chicken plasminogen. Microbial pathogenesis 51, 285-290.
- Dahl, H.H., Hunt, S.M., Hutchison, W.M., Brown, G.K., 1987. The human pyruvate dehydrogenase complex. Isolation of cDNA clones for the E1 alpha subunit, sequence analysis, and characterization of the mRNA. The Journal of biological chemistry 262, 7398-7403.
- Dallo, S.F., Kannan, T.R., Blaylock, M.W., Baseman, J.B., 2002. Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae. Mol Microbiol 46, 1041-1051.
- Frey, M.L., Hanson, R.P., Andrson, D.P., 1968. A medium for the isolation of avian mycoplasmas. American journal of veterinary research 29, 2163-2171.
- Gao, X., Bao, S., Xing, X., Fu, X., Zhang, Y., Xue, H., Wen, F., Wei, Y., 2018. Fructose-1,6-bisphosphate aldolase of Mycoplasma bovis is a plasminogen-binding adhesin. Microbial pathogenesis 124, 230-237.
- Giambrone, J.J., Eidson, C.S., Kleven, S.H., 1977. Effect of infectious bursal disease on the response of chickens to Mycoplasma synoviae, Newcastle disease virus, and infectious bronchitis virus. Am J Vet Res 38, 251-253.
- Khiari, A.B., Gueriri, I., Mohammed, R.B., Mardassi, B.B., 2010. Characterization of a variant vlhA gene of Mycoplasma synoviae, strain WVU 1853, with a highly divergent haemagglutinin region. BMC Microbiol 10,

6.

- Kleven, S.H., 1998. Mycoplasmas in the etiology of multifactorial respiratory disease. *Poultry science* 77, 1146-1149.
- Landman, W.J., 2014. Is *Mycoplasma synoviae* outrunning *Mycoplasma gallisepticum*? A viewpoint from the Netherlands. *Avian Pathol* 43, 2-8.
- Limpavithayakul, K., Sasipreeyajan, J., Pakpinyo, S., 2016. Characterization of Thai *Mycoplasma synoviae* Isolates by Sequence Analysis of Partial *vlhA* Gene. *Avian Dis* 60, 810-816.
- Linn, T.C., Pettit, F.H., Hucho, F., Reed, L.J., 1969a. Alpha-keto acid dehydrogenase complexes. XI. Comparative studies of regulatory properties of the pyruvate dehydrogenase complexes from kidney, heart, and liver mitochondria. *Proceedings of the National Academy of Sciences of the United States of America* 64, 227-234.
- Linn, T.C., Pettit, F.H., Reed, L.J., 1969b. Alpha-keto acid dehydrogenase complexes. X. Regulation of the activity of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. *Proceedings of the National Academy of Sciences of the United States of America* 62, 234-241.
- May, M., Kleven, S.H., Brown, D.R., 2007. Sialidase activity in *Mycoplasma synoviae*. *Avian Dis* 51, 829-833.
- Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., 2014. The pyruvate dehydrogenase complexes: structure-based function and regulation. *J Biol Chem* 289, 16615-16623.
- Patel, M.S., Roche, T.E., 1990. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. *FASEB J* 4, 3224-3233.
- Payton, M.A., McCullough, W., Roberts, C.F., Guest, J.R., 1977. Two unlinked genes for the pyruvate dehydrogenase complex in *Aspergillus nidulans*. *J Bacteriol* 129, 1222-1226.
- Perham, R.N., 1991. Domains, motifs, and linkers in 2-oxo acid dehydrogenase multienzyme complexes: a paradigm in the design of a multifunctional protein. *Biochemistry* 30, 8501-8512.
- Reed, L.J., 2001. A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. *J Biol Chem* 276, 38329-38336.
- Rhoades, K.R., 1977. Turkey sinusitis: synergism between *Mycoplasma synoviae* and *Mycoplasma meleagridis*. *Avian Dis* 21, 670-674.
- Salzillo, M., Vastano, V., Capri, U., Muscariello, L., Marasco, R., 2017. Pyruvate dehydrogenase subunit beta of *Lactobacillus plantarum* is a collagen adhesin involved in biofilm formation. *J Basic Microbiol* 57, 353-357.
- Song, Z., Li, Y., Liu, Y., Xin, J., Zou, X., Sun, W., 2012. alpha-Enolase, an adhesion-related factor of *Mycoplasma bovis*. *PloS one* 7, e38836.
- Springer, W.T., Luskus, C., Pourciau, S.S., 1974. Infectious bronchitis and mixed infections of *Mycoplasma synoviae* and *Escherichia coli* in gnotobiotic chickens. I. Synergistic role in the airsacculitis syndrome. *Infect Immun* 10, 578-589.
- Sun, Z., Fu, P., Wei, K., Zhang, H., Zhang, Y., Xu, J., Jiang, F., Liu, X., Xu, W., Wu, W., 2014. Identification of novel immunogenic proteins from *Mycoplasma bovis* and establishment of an indirect ELISA based on recombinant E1 beta subunit of the pyruvate dehydrogenase complex. *PLoS One* 9, e88328.
- Taylor, M.P., Eley, K.L., Martin, S., Tuffin, M.I., Burton, S.G., Cowan, D.A., 2009. Thermophilic ethanologensis:

422 future prospects for second-generation bioethanol production. Trends Biotechnol 27, 398-405.

423 Thomas, C., Jacobs, E., Dumke, R., 2013. Characterization of pyruvate dehydrogenase subunit B and enolase as

424 plasminogen-binding proteins in *Mycoplasma pneumoniae*. Microbiology 159, 352-365.

425 Van Zyl, L.J., Taylor, M.P., Eley, K., Tuffin, M., Cowan, D.A., 2014. Engineering pyruvate decarboxylase-

426 mediated ethanol production in the thermophilic host *Geobacillus thermoglucosidasius*. Appl Microbiol

427 Biotechnol 98, 1247-1259.

428 Vardaman, T.H., Deaton, J.W., Feece, F.N., 1975. Serological responses of broiler-type chickens, with and without

429 Newcastle disease and infectious Bronchitis vaccine, to experimental infection with *Mycoplasma synoviae* by

430 foot pad, air sac and aerosol. Poult Sci 54, 737-741.

431 Vastano, V., Salzillo, M., Siciliano, R.A., Muscariello, L., Sacco, M., Marasco, R., 2014. The E1 beta-subunit of

432 pyruvate dehydrogenase is surface-expressed in *Lactobacillus plantarum* and binds fibronectin. Microbiol Res

433 169, 121-127.

434 Wetzel, A.N., Lefevre, K.M., Raviv, Z., 2010. Revised *Mycoplasma synoviae* vlhA PCRs. Avian Dis 54, 1292-

435 1297.

436

Figure legends

Fig. 1 Analysis of the expression of recombinant proteins using SDS-PAGE followed by Coomassie blue staining. M: Pre-stained protein molecular weight marker (SM1811, Fermentas); Lane 1: Precipitation of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhA; Lane 2: Supernatant of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhA; Lane 3: Total cellular proteins of *E. coli* BL21 (DE3) cells transformed by pET-28a (+); Lane 4: Total cellular proteins of *E. coli* BL21 (DE3) cells transformed by pET-pdhA; Lane 5: Precipitation of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhB; Lane 6: Supernatant of lysate of *E. coli* BL21(DE3) cells transformed by pET-pdhB.

Fig.2 Analysis of purified recombinant proteins using SDS-PAGE followed by Coomassie blue staining. M: Pre-stained protein molecular weight marker (SM1811, Fermentas); Lane 1: Purified rMSPDHA; Lane 2: Purified rMSPDHB.

Fig. 3 Western blot analysis of rabbit anti-rMSPDHA and anti-rMSPDHB sera. A1: Western blot analysis of rabbit anti-rMSPDHA serum; A2: Negative serum from rabbit; Lane 1: Purified rMSPDHA protein; Lane 2: Total proteins of MS WVU1853 strain; Lane 3: BSA control. B1: Western blot analysis of rabbit anti-rMSPDHB serum; B2: Negative serum from rabbit; Lane 1: Purified rMSPDHB protein; Lane 2: Total proteins of MS WVU1853 strain; Lane 3: BSA control

Fig. 4 Western blot analysis of localization of MSPDHA and MSPDHB. Panel A: Western blot analysis using anti-rMSPDHA; Panel B: Western blot analysis using anti-rMSPDHB; Lanes 1, 5: Purified rMSPDHA and rMSPDHB, used as positive control; Lanes 2, 6: Membrane proteins of MS; Lanes 3, 7: Cytosolic proteins of MS; Lanes 4, 8: BSA was used as negative control.

26

27 **Fig. 5** ELISA of MSPDHA and MSPDHB localization. Panel A: ELISA of PDHA distribution
28 in the membrane and soluble cytosolic protein fractions of MS cells using anti-rMSPDHA;
29 Panel B: ELISA of PDHB distribution in the membrane and soluble cytosolic protein fractions
30 of MS cells using anti-rMSPDHB.

31

32 **Fig.6** Western blot analysis of the binding ability of rMSPDHA and rMSPDHB to chicken Plg
33 or human Fn. Panel A: Western blot analysis using anti-rMSPDHA; Panel B: Western blot
34 analysis using anti-rMSPDHB; Lane 1: Chicken Plg; Lane 3: Human Fn; Lanes 2, 4: BSA.

35

36 **Fig.7** ELISA of MSPDHA and MSPDHB binding to chicken Plg or human Fn. (A) ELISA of
37 the binding ability of rMSPDHA to chicken Plg. (B) ELISA of the binding ability of rMSPDHB
38 to chicken Plg. (C) ELISA of the binding ability of rMSPDHA to human Fn. (D) ELISA of the
39 binding ability of rMSPDHB to human Fn.

40

41 **Fig.8** Adherence and adherence inhibition assays. IA: Adherence of *E. coli* cells harboring
42 InaZNEGFP-PDHA to DF-1 cells; IB: Adherence of *E. coli* cells harboring InaZNEGFP to
43 DF-1 cells; IC: Adherence inhibition by rabbit anti-rMSPDHA sera. IIA: Adherence of *E. coli*
44 cells harboring InaZNEGFP-PDHB to DF-1 cells; IIB: Adherence of *E. coli* cells harboring
45 InaZNEGFP to DF-1 cells; IIC: Adherence inhibition by rabbit anti-rMSPDHB sera.

46

kDa

M

1

2

3

4

5

6

170

130

95

72

55

43

36

26

←44kDa

←39kDa

A

The distribute of PDHA in different fractions of MS

B

The distribute of PDHB in different fractions of MS

A **B** **C** **D**

I

II

Table 1 Primers used in this study

The name of the primer	Primer sequences (5'→3')	Localization (nt)
pdhA-F1	GGAGGATCC ^a TCAACAAAATACAA	1–162
pdhA-R1	GATAAAACCATC ^b CATTTGTAACCT	
pdhA-F2	AGGTTACAAATGG ^b ATGGTTTATC	
pdhA-R2	TGGTAGGAAC ^b CAATCTTTTTTCTTGT	162–300
pdhA-F3	ACAAGAAAAAAGATTGG ^b TTCTACCA	
pdhA-R3	TCGTTACCGTTC ^b CAATATAACATTTG	
pdhA-F4	CAAATGTTATATTGG ^b AACGGTAACGA	300–375
pdhA-R4	CAAAATACAGCAGGC ^b CAGCTTCTAACT	
pdhA-F5	AGTTAGAAGCTGG ^b CCTGCTGTATTTTG	
pdhA-R5	TTGAAATTGCC ^b CATTGGTTGTTA	588–621
pdhA-F6	TAACAACCAATGG ^b GCAATTTCAA	
pdhA-R6	GCCTTGTCTC ^b CAAGTTACAAATCC	
pdhA-F7	GGAATTTGTAACCTGG ^b AGACAAGGC	807–885
pdhA-R7	TGCATTGGTTCC ^b CATACTTCTTG	
pdhA-F8	CAAGAAGTATGG ^b GAACCAATGCA	
pdhA-R8	AGAGAATCAGCC ^b CAGATTTTTTCA	885–960
pdhA-F9	TGAAAAAATCTGG ^b GCTGATTCTCT	
pdhA-R9	TTACTCGAG ^a ATTATTTCCCTCCG	
pdhB-F	GGAGGATCC ^a ATGTCTGATAAAAAATAACAG	960–1125
pdhB-R	TTACTCGAG ^a CTAAAATTAAATGAAGTAACT	

^aRestriction sites of GGATCC and CTCGAG for endonuclease *Bam*HI and *Xho*I are shown in underlined italics.

^bNucleotide substitutions are shown in boldface.

^cLocalization was based on the nucleotide sequence of MS 53 *pdhA* (Gene ID:3564398) and *pdhB* (Gene ID:3564399) genes.

Table 2 Mycoplasmacidal activity of rabbit anti-rMSPDHA/anti-rMSPDHB sera

Sera Type	Mean CFU of MS (10^4)	Mycoplasmacidal coefficient (%)
MS positive sera	10	96.5*
Rabbit anti-rMSPDHA sera	100	65.6*
Rabbit anti-rMSPDHB sera	204	29.89*
pre-immune rabbit sera	291	—

*P< 0.01, compared with the corresponding group using pre-immune rabbit serum.

Table 3 CFU values of different treatment groups

Serum	Mean CFU of MS(10^4)	Adhesion inhibition rate(%)
Rabbit anti MS positive sera	60	93.33*
Rabbit anti-rMSPDHA sera	132	85.33*
Rabbit anti-rMSPDHB sera	170	81.11*
pre-immune rabbit sera	900	——

*P < 0.01, compared with the corresponding group using pre-immune rabbit serum(negative control).